Bosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers

Bibliography

• MARICQ HR, WEINRICH MC, KEIL JE et al.: Prevalence of scleroderma spectrum disorders in the general population of South Carolina. Arthritis Rheum. (1989) 32(8):998-1006.
   PubMed Web of Science ®Google Scholar
• STEEN VD, CONTE C, OWENS GR, MEDSGER TA Jr: Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum. (1994) 37(9):1283-1289.
   PubMedGoogle Scholar
• RUBIN LJ: Primary pulmonary hypertension. N. Engl. J. Med. (1997) 336(2):111-117.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, GALIE N, RUBIN LJ et al.: Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):5S-12S.
   PubMed Web of Science ®Google Scholar
• DENG Z, MORSE JH, SLAGER SL et al.: Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am. J. Hum. Genet. (2000) 67(3):737-744.
   PubMed Web of Science ®Google Scholar
• LANE KB, MACHADO RD, PAUCIULO MW et al.: Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat. Genet. (2000) 26(1):81-84.
   PubMed Web of Science ®Google Scholar
• CHRISTMAN BW, MCPHERSON CD, NEWMAN JH et al.: An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. (1992) 327(2):70-75.
   PubMed Web of Science ®Google Scholar
• GIAID A, SALEH D: Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. (1995) 333(4):214-221.
   PubMed Web of Science ®Google Scholar
• HERVE P, LAUNAY JM, SCROBOHACI ML et al.: Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. (1995) 99(3):249-254.
   PubMed Web of Science ®Google Scholar
• KAKISHITA M, NISHIKIMI T, OKANO Y et al.: Increased plasma levels of adrenomedullin in patients with pulmonary hypertension. Clin. Sci. (1999) 96(1):33-39.
   PubMed Web of Science ®Google Scholar
• PETKOV V, MOSGOELLER W, ZIESCHE R et al.: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. (2003) 111(9):1339-1346.
   PubMed Web of Science ®Google Scholar
• KAHALEH B, MEYER O, SCORZA R: Assessment of vascular involvement. Clin. Exp. Rheumatol. (2003) 21(3 Suppl. 29):S9-S14.
   Google Scholar
• STEEN VD: Autoantibodies in systemic sclerosis. Semin. Arthritis Rheum. (2005) 35(1):35-42.
   PubMed Web of Science ®Google Scholar
• JIMENEZ SA, DERK CT: Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann. Intern. Med. (2004) 140(1):37-50.
   PubMed Web of Science ®Google Scholar
• ALLEN SW, CHATFIELD BA, KOPPENHAFER SA, SCHAFFER MS, WOLFE RR, ABMAN SH: Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am. Rev. Respir. Dis. (1993) 148(2):519-522.
   Google Scholar
• VINCENT JA, ROSS RD, KASSAB J, HSU JM, PINSKY WW: Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood flow. Am. J. Cardiol. (1993) 71(13):1204-1207.
   PubMed Web of Science ®Google Scholar
• STEEN V, MEDSGER TA Jr: Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. (2003) 48(2):516-522.
   PubMed Web of Science ®Google Scholar
• D’ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. (1991) 115(5):343-349.
   PubMed Web of Science ®Google Scholar
• MUKERJEE D, ST GEORGE D, COLEIRO B et al.: Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann. Rheum. Dis. (2003) 62(11):1088-1093.
   PubMed Web of Science ®Google Scholar
• KAWUT SM, TAICHMAN DB, ARCHER-CHICKO CL, PALEVSKY HI, KIMMEL SE: Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. Chest (2003) 123(2):344-350.
   PubMed Web of Science ®Google Scholar
• MIYAMOTO S, NAGAYA N, SATOH T et al.: Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. (2000) 161(2 Pt 1):487-492.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332(6163):411-415.
   PubMed Web of Science ®Google Scholar
• HASSOUN PM, THAPPA V, LANDMAN MJ, FANBURG BL: Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc. Soc. Exp. Biol. Med. (1992) 199(2):165-170.
   PubMed Web of Science ®Google Scholar
• RUBANYI GM, POLOKOFF MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. (1994) 46(3):325-415.
   PubMed Web of Science ®Google Scholar
• LEVIN ER: Endothelins. N. Engl. J. Med. (1995) 333(6):356-363.
   PubMed Web of Science ®Google Scholar
• HAYNES WG, WEBB DJ: The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin. Sci. (1993) 84(5):485-500.
   PubMed Web of Science ®Google Scholar
• ORTEGA MATEO A, DE ARTINANO AA: Highlights on endothelins: a review. Pharmacol. Res. (1997) 36(5):339-351.
   Google Scholar
• ARAI H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348(6303):730-732.
   PubMed Web of Science ®Google Scholar
• SAKURAI T, YANAGISAWA M, TAKUWA Y et al.: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature (1990) 348(6303):732-735.
   PubMed Web of Science ®Google Scholar
• HIRATA Y, EMORI T, EGUCHI S et al.: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J. Clin. Invest. (1993) 91(4):1367-1373.
   PubMed Web of Science ®Google Scholar
• DE NUCCI G, GRYGLEWSKI RJ, WARNER TD, VANE JR: Receptor-mediated release of endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells is coupled. Proc. Natl Acad. Sci. USA (1988) 85(7):2334-2338.
   Google Scholar
• DUPUIS J, GORESKY CA, FOURNIER A: Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J. Appl. Physiol. (1996) 81(4):1510-1515.
   PubMed Web of Science ®Google Scholar
• SEO B, OEMAR BS, SIEBENMANN R, VON SEGESSER L, TF LUSCHER: Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89(3):1203-1208.
   PubMed Web of Science ®Google Scholar
• POLLOCK DM, KEITH TL, HIGHSMITH RF: Endothelin receptors and calcium signaling. Faseb J. (1995) 9(12):1196-1204.
   PubMed Web of Science ®Google Scholar
• DUPUIS J, JASMIN JF, PRIE S, CERNACEK P: Importance of local production of endothelin-1 and of the ET(B)Receptor in the regulation of pulmonary vascular tone. Pulm. Pharmacol. Ther. (2000) 13(3):135-140.
   Google Scholar
• CLOZEL M, BREU V, BURRI K et al.: Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature (1993) 365(6448):759-761.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V, GRAY GA et al.: Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. (1994) 270(1):228-235.
   PubMed Web of Science ®Google Scholar
• SUTSCH G, KIOWSKI W, YAN XW et al.: Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation (1998) 98(21):2262-2268.
   PubMed Web of Science ®Google Scholar
• MYLONA P, CLELAND JG: Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur. J. Heart. Fail. (1999) 1(2):197-200.
   Google Scholar
• KRUM H, VISKOPER RJ, LACOURCIERE Y, BUDDE M, CHARLON V: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N. Engl. J. Med. (1998) 338(12):784-790.
   PubMed Web of Science ®Google Scholar
• DINGEMANSE J, VAN GIERSBERGEN PL: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. (2004) 43(15):1089-1115.
   PubMed Web of Science ®Google Scholar
• MAY A, GIJSMAN HJ, WALLNOFER A, JONES R, DIENER HC, FERRARI MD: Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain (1996) 67(2-3):375-378.
   PubMed Web of Science ®Google Scholar
• BENIGNI A, REMUZZI G: Endothelin antagonists. Lancet (1999) 353(9147):133-138.
   PubMed Web of Science ®Google Scholar
• CHEN SJ, CHEN YF, MENG QC, DURAND J, DICARLO VS, OPARIL S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol. (1995) 79(6):2122-2131.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, WALLMAN LL, JONES R et al.: Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 102(4):411-418.
   PubMed Web of Science ®Google Scholar
• BINET I, WALLNOFER A, WEBER C, JONES R, THIEL G: Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A. Kidney Int. (2000) 57(1):224-231.
   PubMed Web of Science ®Google Scholar
• WEBER C, SCHMITT R, BIRNBOECK H et al.: Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects. Clin. Pharmacol. Ther. (1996) 60(2):124-137.
   PubMed Web of Science ®Google Scholar
• GIRGIS RE, CHAMPION HC, DIETTE GB, JOHNS RA, PERMUTT S, SYLVESTER JT: Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am. J. Respir. Crit. Care Med. (2005) 172(3):352-357.
   PubMed Web of Science ®Google Scholar
• GIANNELLI G, IANNONE F, MARINOSCI F, LAPADULA G, ANTONACI S: The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr. Med. Res. Opin. (2005) 21(3):327-332.
   PubMedGoogle Scholar
• WEBER C, SCHMITT R, BIRNBOECK H et al.: Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J. Clin. Pharmacol. (1999) 39(7):703-714.
   PubMed Web of Science ®Google Scholar
• WEBER C, GASSER R, HOPFGARTNER G: Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab. Dispos. (1999) 27(7):810-815.
   PubMed Web of Science ®Google Scholar
• VAN GIERSBERGEN PL, HALABI A, DINGEMANSE J: Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br. J. Clin. Pharmacol. (2002) 53(6):589-595.
   PubMed Web of Science ®Google Scholar
• VAN GIERSBERGEN PL, POPESCU G, BODIN F, DINGEMANSE J: Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. J. Clin. Pharmacol. (2003) 43(1):15-22.
   PubMed Web of Science ®Google Scholar
• DINGEMANSE J, GIERSBERGEN PL: Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist. Int. J. Clin. Pharmacol. Ther. (2002) 40(7):310-316.
   Google Scholar
• BARST RJ, IVY D, DINGEMANSE J et al.: Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. (2003) 73(4):372-382.
   PubMed Web of Science ®Google Scholar
• VAN GIERSBERGEN PL, GNERRE C, TREIBER A, DINGEMANSE J, MEYER UA: Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor. Eur. J. Pharmacol. (2002) 450(2):115-121.
   PubMed Web of Science ®Google Scholar
• WANG E, CASCIANO CN, CLEMENT RP, JOHNSON WW: HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. (2001) 18(6):800-806.
   PubMed Web of Science ®Google Scholar
• VAN GIERSBERGEN PL, TREIBER A, CLOZEL M, BODIN F, DINGEMANSE J: In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin. Pharmacol. Ther. (2002) 71(4):253-262.
   PubMed Web of Science ®Google Scholar
• WEBER C, BANKEN L, BIRNBOECK H, SCHULZ R: Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin. J. Clin. Pharmacol. (1999) 39(8):847-854.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SIMONNEAU G, SITBON O et al.: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358(9288):1119-1123.
   PubMed Web of Science ®Google Scholar
• SCHULZE-NEICK I, GILBERT N, EWERT R et al.: Adult patients with congenital heart disease and pulmonary arterial hypertension: first open prospective multicenter study of bosentan therapy. Am. Heart J. (2005) 150(4):716.
   PubMedGoogle Scholar
• SITBON O, GRESSIN V, SPEICH R et al.: Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 170(11):1212-1217.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, KRAMM T, WILKENS H et al.: Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 128(4):2363-2367.
   PubMed Web of Science ®Google Scholar
• BONDERMAN D, NOWOTNY R, SKORO-SAJER N et al.: Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 128(4):2599-2603.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, HALANK M, MARX C et al.: Bosentan therapy for portopulmonary hypertension. Eur. Respir. J. (2005) 25(3):502-508.
   PubMed Web of Science ®Google Scholar
• GATZOULIS MA, ROGERS P, LI W et al.: Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int. J. Cardiol. (2005) 98(1):147-151.
   PubMed Web of Science ®Google Scholar
• ROSENZWEIG EB, IVY DD, WIDLITZ A et al.: Effects of long-term bosentan in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46(4):697-704.
   PubMed Web of Science ®Google Scholar
• MAIYA S, HISLOP AA, FLYNN Y, HAWORTH SG: Response to bosentan in children with pulmonary hypertension. Heart.
   Google Scholar
• SIMPSON CM, PENNY DJ, COCHRANE AD et al.: Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J. Heart Lung Transplant. (2006) 25(4):469-473.
   Google Scholar
• MCLAUGHLIN VV, SITBON O, BADESCH DB et al.: Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. (2005) 25(2):244-249.
   PubMed Web of Science ®Google Scholar
• RICH S, DANTZKER DR, AYRES SM et al.: Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. (1987) 107(2):216-223.
   PubMed Web of Science ®Google Scholar
• JOGLEKAR A, TSAI FS, MCCLOSKEY DA, WILSON JE, SEIBOLD JR, RILEY DJ: Bosentan in pulmonary arterial hypertension secondary to scleroderma. J. Rheumatol. (2006) 33(1):61-68.
   PubMedGoogle Scholar
• GIRGIS RE, MATHAI SC, KRISHNAN JA, WIGLEY FM, HASSOUN PM: Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J. Heart Lung Transplant. (2005) 24(10):1626-1631.
   PubMed Web of Science ®Google Scholar
• WILLIAMS MH, DAS C, HANDLER CE et al.: Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2006) 92:926-932.
   PubMed Web of Science ®Google Scholar
• WILKINS MR, PAUL GA, STRANGE JW et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. (2005) 171(11):1292-1297.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, BARST RJ, ROBBINS IM et al.: Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur. Respir. J. (2004) 24(3):353-359.
   PubMed Web of Science ®Google Scholar
• MCLAUGHLIN VA, OUDIZ R, FROST A et al.: A randomized, double-blind, placebo-controlled study of iloprost inhalation as add-on therapy to bosentan in pulmonary arterial hypertension. Chest (2005) 128(4 Suppl.):160s.
   Google Scholar
• HALANK M, KOLDITZ M, OPITZ C, HOEFFKEN G, EWERT R: Successful switch from long-term intravenous iloprost to non-invasive combination therapy in idiopathic pulmonary arterial hypertension. Wien. Klin. Wochenschr. (2006) 118(1-2):54-59.
   Google Scholar
• SULEMAN N, FROST AE: Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest (2004) 126(3):808-815.
   PubMed Web of Science ®Google Scholar
• HOEPER MM, FAULENBACH C, GOLPON H, WINKLER J, WELTE T, NIEDERMEYER J: Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur. Respir. J. (2004) 24(6):1007-1010.
   PubMed Web of Science ®Google Scholar
• PAUL GA, GIBBS JS, BOOBIS AR, ABBAS A, WILKINS MR: Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. (2005) 60(1):107-112.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, FROST A et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 169(4):441-447.
   PubMed Web of Science ®Google Scholar
• GALIE N, BADESCH D, OUDIZ R et al.: Ambrisentan therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2005) 46(3):529-535.
   PubMed Web of Science ®Google Scholar
• HUMBERT M, CABANE J: Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan. Rheumatology (2003) 42(1):191-193.
   PubMed Web of Science ®Google Scholar
• RAMOS-CASALS M, BRITO-ZERONP, NARDI N et al.: Successful treatment of severe Raynaud’s phenomenon with bosentan in four patients with systemic sclerosis. Rheumatology (2004) 43(11):1454-1456.
   PubMed Web of Science ®Google Scholar
• SEIBOLD J et al.: Bosentan prevents occurrence but does not speed the healing of digital ulcers in patients with systemic sclerosis. Arthritis Rheum. (2005) L2:552 (Abstract).
   Google Scholar
• KORN JH, MAYES M, MATUCCI CERINIC M et al.: Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. (2004) 50(12):3985-3993.
   PubMed Web of Science ®Google Scholar
• SHI-WEN X, CHEN Y, DENTON CP et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell (2004) 15(6):2707-2719.
   Google Scholar
• HOCHER B, SCHWARZ A, FAGAN KA et al.: Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. (2000) 23(1):19-26.
   PubMed Web of Science ®Google Scholar
• CAMBREY AD, HARRISON NK, DAWES KE et al.: Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mol. Biol. (1994) 11(4):439-445.
   PubMed Web of Science ®Google Scholar
• ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. (1997) 151(3):831-841.
   PubMed Web of Science ®Google Scholar
• PARK SH, SALEH D, GIAID A, MICHEL RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. (1997) 156(2 Pt 1):600-608.
   PubMed Web of Science ®Google Scholar
• SEGAL ES, VALETTE C, OSTER L et al.: Risk management strategies in the postmarketing period : safety experience with the US and European bosentan surveillance programmes. Drug Saf. (2005) 28(11):971-980.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SITBON O, BARST RJ, MANES A, RUBIN LJ: Endothelin receptor antagonists in pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2004) 43(12 Suppl. S):62S-67S.
   PubMed Web of Science ®Google Scholar
• KURIHARA Y, KURIHARA H, SUZUKI H et al.: Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature (1994) 368(6473):703-710.
   PubMed Web of Science ®Google Scholar
• COCEANI F, KELSEY L: Endothelin-1 release from lamb ductus arteriosus: relevance to postnatal closure of the vessel. Can. J. Physiol. Pharmacol. (1991) 69(2):218-221.
   PubMed Web of Science ®Google Scholar
• RICH S (Ed): Primary pulmonary hypertension. Executive Summary from the World Symposium on Primary Pulmonary Hypertension. Evian, France (1998).
   Google Scholar